Despite years of fully suppressive antiretroviral therapy (ART), HIV persists in its hosts and is never eradicated. One major barrier to eradication is that the virus infects multiple cell types that may individually contribute to HIV persistence. Tissue macrophages are critical contributors to HIV pathogenesis [1] [2] [3] ; however, their specific role in HIV persistence during long-term suppressive ART has not been established [4] [5] [6] . Using humanized myeloid-only mice (MoM), we demonstrate that HIV infection of tissue macrophages is rapidly suppressed by ART, as reflected by a rapid drop in plasma viral load and a dramatic decrease in the levels of cell-associated viral RNA and DNA. No viral rebound was observed in the plasma of 67% of the ART-treated animals at 7 weeks after ART interruption, and no replication-competent virus was rescued from the tissue macrophages obtained from these animals. In contrast, in a subset of animals (~33%), a delayed viral rebound was observed that is consistent with the establishment of persistent infection in tissue macrophages. These observations represent the first direct evidence, to our knowledge, of HIV persistence in tissue macrophages in vivo.
Humanized bone marrow, liver, thymus (BLT) mice are reconstituted with human T cells and macrophages, both of which are targets for HIV infection in vivo [7] [8] [9] [10] [11] . Use of HIV-infected mice previously reconstituted with human macrophages and T cells permits assessment of the effect of ART on tissue macrophages in the presence of T cells, while allowing for interactions between the two cell types. We infected BLT mice (n = 18) with macrophage-tropic viruses (HIV-1 CH040 or HIV-1 CH040-4013env ) 7 and monitored plasma viremia longitudinally ( Fig. 1a and Supplementary Table 1) . Thirteen mice at 5 weeks after infection were treated once daily with triple-combination ART, in which three antiretroviral drugs were used [12] [13] [14] . Within 2 weeks of ART initiation, we observed a significant decrease in the plasma viremia of treated (black line) versus untreated (gray line) mice ( Fig. 1a ; Mann-Whitney test). This corresponded to an average 1.3-log reduction in plasma viral RNA after 1 week of treatment (Fig. 1b) . We used the change in viral load after ART initiation to estimate the half-life of productively infected cells in BLT mice, which was approximately 2.4 d (Fig. 1c) , similar to the previous estimate of ~2 d in humans [15] [16] [17] .
To address the effect of ART specifically on infected tissue macrophages, cells were pooled from the spleen, liver, lung, and bone marrow of individual ART-treated or untreated BLT mice. A stepwise magnetic cell sorting strategy was used to isolate T cells and macrophages ( Fig. 1d and Supplementary Fig. 1a-c) 7 . We were able to detect cell-associated viral DNA (Fig. 1e) and RNA (Fig. 1f) in the purified T cell fractions of untreated mice. In ART-treated mice, the levels of viral DNA and RNA in T cells were reduced but readily detectable (Fig. 1e,f) . In the purified macrophage fraction, we were able to readily detect viral DNA and RNA in untreated mice; however, the levels of viral DNA and RNA in tissue macrophages from ART-treated mice were below our level of detection using real-time PCR assays (Fig. 1e,f) . We then conducted structuredtreatment-interruption studies to assess the presence of persistently infected cells containing replication-competent virus (Fig. 1g,h) 12 . In all cases, HIV rebound was observed by 2 weeks after therapy interruption, which corresponds to a time to rebound within the range observed for patients with HIV 18 . Considering the absence of detectable viral RNA and DNA in macrophages isolated from ARTtreated BLT mice, the rapid rebound observed ostensibly results from virus present in T cells.
MoM are generated by transplanting human CD34 + hematopoietic stem cells into NOD/SCID mice, which are unable to support human T cell development 19 . MoM are systemically reconstituted with human myeloid and B cells, but not human T cells ( Supplementary  Fig. 2 ) 7 .We have previously shown that MoM are susceptible to HIV infection and can efficiently sustain systemic HIV replication over several months 7 . MoM were used to avoid the confounding complications of having an excess of T cells present during the evaluation of HIV persistence in macrophages. We infected MoM (n = 14) with the same macrophage-tropic HIV isolates used for the BLT mice in Figure  1 (Supplementary Table 1 ) and monitored infection over time in the absence (n = 6) or presence (n = 8) of ART (Supplementary Fig. 3) . In all treated MoM, we noted a rapid and significant drop in plasma HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy viremia below the limit of detection relative to untreated MoM ( Fig. 2a ; Mann-Whitney test). After 1 week of ART, this drop corresponded to an average 1.8-log reduction in plasma viral RNA levels (Fig. 2b) . This reduction in plasma viral RNA levels was significantly larger than the reduction observed in BLT mice ( Fig. 1b; Mann-Whitney test, P = 0.039). Using the change in viral load after ART initiation, we estimated the half-life of productively infected macrophages in MoM to be 1.05 d (Fig. 2c) , which is notably shorter than the estimated half-life of infected T cells in humans and BLT mice ( Fig. 1c; MannWhitney test, P = 0.0002) [15] [16] [17] . Although the half-life of HIV-infected macrophages in MoM is shorter than that previously estimated for macrophages in macaques infected with simian/human immunodeficiency virus (SHIV) 20 , our results are consistent with the more recent estimate of 1.33 d in CD4 + T cell-depleted macaques infected with simian immunodeficiency virus (SIV) on combination ART 21 .
We determined the levels of cell-associated viral DNA and RNA in tissue macrophages isolated from the liver, lung, spleen, and bone marrow of untreated or ART-treated MoM (Supplementary Table 1) . Notably, the levels of viral DNA in 18 of 24 samples from 6 ARTtreated MoM were below the level of detection (empty boxes in Fig. 2d; log-rank test, P = 0.0003, P = 0.002, P = 0.007, and P = 0.0003 for liver, lung, spleen, and bone marrow, respectively). Using an ultrasensitive quantitative droplet PCR technique, we demonstrated that HIV was integrated into the genome in a portion of the HIV DNA samples in the ART-treated group (a total of four samples were analyzed) and that the levels of integrated HIV DNA were significantly lower in treated animals ( Supplementary Fig. 3c ). In accordance with this significant decrease in viral DNA levels, the viral RNA levels of 11 of the 15 samples analyzed were also below the level of detection in 5 ART-treated MoM (empty boxes in Fig. 2e ; log-rank test, P = 0.005, P = 0.008, P = 0.008, and P = 0.001 for liver, lung, spleen, and bone marrow, respectively). This difference in HIV DNA and RNA levels between treated and untreated mice did not result from a loss of macrophages in the tissues of treated mice ( Fig. 2f ; Mann-Whitney test, P > 0.05 for all tissue types). The limited detection of viral DNA and RNA from ART-treated MoM samples is consistent with our data obtained from purified macrophages isolated from the tissues of ART-treated BLT mice (Fig. 1e,f) .
To determine whether HIV persists in infected tissue macrophages and can re-establish persistent infection after ART treatment, we Table 1 ). In sharp contrast with what was observed in BLT mice, where viral rebound was observed within 2 weeks of therapy discontinuation in all animals (n = 5), no viral rebound was observed in 6 of 9 MoM in an extended timeframe (greater than 7 weeks) (Fig. 3a) . Upon further examination of tissue macrophages isolated from MoM in which no HIV rebound was observed, we detected no viral DNA or RNA ( RNA (e) levels were measured in the liver, lung, spleen, and bone marrow of ART-treated (n = 6; gray squares) and untreated (n = 8; black squares) MoM. Undetectable samples are represented by an empty black box shown at the limit of detection for that sample (dependent on the number of cells available for analysis). Viral DNA and RNA levels were normalized per 100,000 human macrophages and compared between treated and untreated mice. A log-rank test was used to account for censoring due to the limits of detection in d and e. (f) There was no difference in the total numbers of human macrophages present in the tissues of ART-treated and untreated MoM (P > 0.05 for all tissue types, Mann-Whitney test). In b-f, horizontal lines represent mean ± s.e.m. P values for a-e are represented as follows: *P < 0.05, **P < 0.01, ***P < 0.001.
persistent, replication-competent virus was present in tissue macrophages isolated from ART-treated MoM in which no rebound was observed, we applied outgrowth assays similar to those previously used in macaques to either quantify virus from infected macrophages 22 or establish SIV eradication after vaccination with an hCMV-based vector 23, 24 . For this purpose, cells obtained from the MoM in which viral rebound was not observed were directly injected into BLT humanized mice, as we have previously described 7 , or were co-cultured with CD8 + -depleted activated allogeneic CD4 + T cells 7, [25] [26] [27] . Plasma or tissue culture supernatants were then monitored for the presence of viral outgrowth; however, no replication-competent virus was rescued from any of the five MoM that were analyzed ( Table 1) . Fewer total numbers of cells were isolated from MoM 19, precluding additional outgrowth analysis for this mouse. In plasma from three of the MoM, we observed viral rebound 7 weeks after ART interruption (Fig. 3b) . We confirmed the absence of human T cells in the tissues of 'rebound' MoM ( Supplementary Fig. 4) . We demonstrated the replication competence of the rebound virus (from MoM 23) to infect both T cells and macrophages using the same outgrowth assays performed on the 'no rebound' MoM ( Supplementary Fig. 5 and Supplementary Table 2 ). Additionally, HIV env was sequenced from the plasma of rebound MoM and compared to the sequence of the original virus used for infection. No mutations were found in MoM 22. In MoM 21 and 23, a point mutation was present, resulting in singleamino-acid changes (I262L and I107S, respectively) in the env sequence (GenBank accession numbers KX825880 and KX825881). In MoM 23, the mutation was present in ~50% of the bulk sequence. A post hoc comparison of mice with and without HIV rebound demonstrated a higher pre-ART viral load (Fig. 3c) and a larger total pre-ART viral burden (as demonstrated by the area under the curve for pre-ART viremia; Fig. 3d ) in the rebound mice (Mann-Whitney test, P = 0.02). No differences were noted between rebound and no-rebound mice in the overall levels of human cells in the blood (Mann-Whitney test, P = 0.381) or the number of tissue macrophages ( Fig. 3e; Mann-Whitney test, P > 0.05). This suggests that, under our experimental conditions, the lack of rebound observed in six of the nine mice was not simply due HIV DNA and RNA analysis and in vivo or in vitro viral outgrowth assays were performed with cells isolated from ART-treated MoM in which plasma viral rebound was not observed. The tissues analyzed for all mice included the spleen, liver, lung, brain, and bone marrow. In MoM 18-20, the gastrointestinal and female reproductive tracts were also analyzed for the presence of HIV DNA. For the viral outgrowth assays, cells isolated from the tissues of MoM were (i) cultured with activated allogeneic CD4 + T cells and culture supernatants were tested for the presence of cell-free HIV RNA by real-time PCR analysis (in vitro method) or (ii) injected into BLT mice and plasma viral load was monitored over time to determine the presence or absence of HIV infection in recipient mice (in vivo method). The total number of cells used for outgrowth analysis is indicated (no. cells). LOD, limit of detection; ND, not determined.
to insufficient numbers of human-derived tissue macrophages, but was due to the absence of productively infected cells capable of restarting the infection. We then used these data to model the likely persistence of HIVinfected macrophages under ART in view of their half-life. Our estimate of approximately 1 d for the half-life of infected macrophages indicates that half of all infected macrophages are lost every day. Therefore, the number of productively infected macrophages under ART would be expected to decay to about 1% after 1 week and to less than 0.00001% of the initial value during the 5 weeks of treatment. The fact that viral rebound was observed 7 weeks after therapy interruption (and was absent in most of the treated MoM) is consistent with the existence of a small population of infected tissue macrophages that persist despite ART, especially when pretreatment viral burden is greatest. As in any study involving the use of a model system, there are some caveats to this analysis. First, the strain of immunodeficient mice used to generate MoM (NOD/SCID mice) develop spontaneous thymic lymphomas, resulting in a relatively short lifespan (9-14 months) 28 . This limitation prevented us from extending our observations of infected MoM after interruption of ART for longer periods of time. Therefore, outgrowth assays were used to confirm the absence of cells containing replication-competent virus. Second, certain interactions between T cells and macrophages may be critical for persistent HIV infection; therefore, our results in MoM may underestimate the frequency of viral rebound from macrophages. However, this is unlikely to be the case, as the disappearance of infected macrophages was noted in both ART-treated, HIV-infected BLT mice and MoM, suggesting that the presence of human T cells is not critical for HIV persistence in human macrophages. Antiretroviral therapy alone is not sufficient to eradicate HIV from the body. Hill et al. indicate that reductions of 2-3 logs in the number of latently infected cells are needed to delay rebound for the time reported herein for MoM 29 . The delay in rebound observed in MoM is greater than that reported for patients initiating ART during the chronic phase of infection 30 and for patients with an ultralow HIV reservoir 18 . Our results indicate that HIV-infected tissue macrophages have a short half-life and that ART alone can significantly reduce the levels of infected tissue macrophages, further demonstrating the critical contribution of T cells to the viral reservoir. Given the short halflife of infected macrophages during ART treatment, it is possible that, under extended ART treatment, no viral rebound from macrophages would be observed in MoM. In patients in whom viral rebound occurs after a long period following ART interruption, the cellular identity and location within the tissue of the HIV reservoir is unknown 31, 32 . However, the fact that viral rebound can be observed in 33% of the infected, virally suppressed mice suggests that macrophages may represent a persistent viral reservoir for HIV. Specialized, long-lived macrophages, such as microglia, are thought to persist in the central nervous system (CNS) for long periods of time despite infection 33, 34 and could thus contribute to viral persistence over time. Therefore, our results show that productively infected tissue macrophages can persist in the host despite effective treatment and can re-establish productive infection after structured treatment interruption.
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